Our CEO Salim Dhanji joined Karen Jagoda at Empowered Patient Podcast to discuss our in vivo CAR program, including our dual CD19/CD22 candidate, limitations of ex-vivo CAR-T therapies & how our approach could make a meaningful difference for patients. 🎧 https://t.co/GDAr4qRBW0
We are pleased to announce that we have engaged Orbiton Financial to provide investor relations and market-awareness services.
🔗 Read the release: https://t.co/wjLYStBJJM
#METX#InVivoCar#TherapeuticmRNA
Welcome to the team, Elizabeth Nomellini, joining us as a Co-op Student from @UBC, where she’s in her fourth year of the Microbiology and Immunology Honours program. We look forward to the perspective she’ll bring to our research in #invivoCAR and therapeutic #mRNA for cancer.
In the final part of our in vivo CAR series, we are featuring our two lead candidates. Each uses a different approach to target the CD19 and CD22 cancer markers. Both hold the promise of treating certain forms of blood cancer and autoimmune disease. 🔗https://t.co/waukLbIhfv
This #WorldCancerResearchDay, we’re highlighting how mRNA could unlock cancer targets known for decades but difficult to drug. We’re applying this to one such target, the STING pathway, with our recent data providing encouraging evidence. 🔗 https://t.co/hcdR4Uf5aM
In an interview with Onyx Newsroom, CEO Salim Dhanji shares how we were founded to solve the challenge of overcoming immune suppression in the tumour microenvironment to allow a patient's own immune system to fight their cancer. 🔗 Read the article: https://t.co/tGyV3K4Ntr
Update: Our #InVivoCAR program yielded two lead constructs & head-to-head preclinical testing is now underway. Also our #therapeuticmRNA program developed a novel liver-detargeted formulation to focus STING expression in the tumour microenvironment. 🔗 https://t.co/eMOhpsfhHe
In part two of our summer series, we explore how in vivo CAR therapy addresses key limitations of traditional CAR therapies. ME Therapeutics is using in vivo CAR to make a highly effective approach to cancer treatment faster, less costly and more available.
In an article for Business Insight Journal, CEO Salim Dhanji explores the potential of in vivo CAR therapy to transform cancer treatment by reprogramming a patient’s immune cells inside the body rather than in a laboratory.
🔗 Read Salim's insights: https://t.co/fzFlj3HloZ
Follow along with our summer series where we explore the concepts behind ME Therapeutics’s in vivo CAR therapy technology: what it is, what problems it solves, and what candidates are in our pipeline. This month: What is in vivo CAR?
Here’s a look at our therapeutic mRNA targeting the STING pathway. Turning on STING is like flicking a switch to make "cold" tumors visible or "hot". In a colorectal cancer model, our candidate led to recruitment of immune cells & reduced tumor growth. https://t.co/d5bNezhoPW
Coming to you from #BIO2026 in San Diego, where we are connecting with investors to discuss our differentiated science both in our in vivo CAR program and therapeutic mRNA program. Email [email protected] to set up a meeting.
#BIOInternationalConvention
We are attending #BIO2026 in San Diego and looking forward to meeting with investors. Connect to learn about our differentiated science, including in vivo CAR and therapeutic mRNA programs targeting the STING pathway. To schedule a meeting, email [email protected].
@CSE News recently sat down with our CEO Salim Dhanji, Ph.D., for their Issuer Update. Salim explains how ME Therapeutics is advancing cancer therapeutics that would re-engineer a patient’s immune cells in their body. Watch the full conversation: https://t.co/Onmg9sj77i
@CSE News recently sat down with our CEO Salim Dhanji, Ph.D., for their Issuer Update. Salim explains how ME Therapeutics is advancing cancer therapeutics that would re-engineer a patient’s immune cells in their body. Watch the full conversation: https://t.co/Onmg9sj77i
On the Stories in Life Sciences Podcast, ME Therapeutics CEO Salim Dhanji discusses with Christopher Wilson the promise of in vivo CAR therapy, the company’s unique path to first-in-human trials, and what it takes to raise capital for biotech in Canada. 🎧 https://t.co/k2eM5NPytG
We are still buzzing from @WebSummit Vancouver & presenting at @CSE_News’s exclusive Capital Tech Connect, alongside other tech companies. Our CEO Dr. Salim Dhanji spoke about how we are advancing nextgen cancer medicines that overcome some of the biggest challenges in the field.
We’ve been invited to pitch at CSE Capital Tech Connect, hosted by the @CSE News during @WebSummit in #Vancouver. Our CEO Salim Dhanji will highlight how our in vivo immune reprogramming approaches represent the next wave of cancer medicines.
https://t.co/R6kC9IQ4Oe
May is #CancerResearchMonth. Research suggests we can expect 29.5M new cases of cancer by 2040. We believe immuno-oncology provides a necessary evolution in cancer care, and we’re proud to be part of the research community pushing this science forward. @AACR